{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:54:30Z","timestamp":1792630470310,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T00:00:00Z","timestamp":1450310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10067-015-3140-6","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T21:51:05Z","timestamp":1450302665000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Infliximab-induced autoantibodies: a multicenter study"],"prefix":"10.1007","volume":"35","author":[{"given":"Jo\u00e3o Luiz Pereira","family":"Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vander","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Arn\u00f3bio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"3140_CR1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.754937","volume":"42","author":"C Eriksson","year":"2013","unstructured":"Eriksson C, Rantap\u00e3\u00e3-Dahlqvist S, Sundqvist KG (2013) Changes in chemokines and their receptors in blood during treatment with TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 42:260\u2013265","journal-title":"Scand J Rheumatol"},{"key":"3140_CR2","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/rheumatology\/keu214","volume":"53","author":"G Moulis","year":"2014","unstructured":"Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 53:1864\u20131871","journal-title":"Rheumatology (Oxford)"},{"key":"3140_CR3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1191\/0961203305lu2240rr","volume":"14","author":"L Rycke De","year":"2005","unstructured":"De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F (2005) The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14:931\u2013937","journal-title":"Lupus"},{"key":"3140_CR4","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M Bant De","year":"2005","unstructured":"De Bant M, Sibilia J, Le L\u00f6et X, Prouzeau S, Fautrel B, Marcelli C et al (2005) Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti- tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545\u2013R551","journal-title":"Arthritis Res Ther"},{"key":"3140_CR5","first-page":"401","volume":"26","author":"C Gonnet-Gracia","year":"2008","unstructured":"Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF\u03b1 blockers. Clin Exp Rheum 26:401\u2013407","journal-title":"Clin Exp Rheum"},{"key":"3140_CR6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0961203314523871","volume":"23","author":"S Ara\u00fajo-Fern\u00e1ndez","year":"2014","unstructured":"Ara\u00fajo-Fern\u00e1ndez S, Ahij\u00f3n-Lana M, Isenberg DA (2014) Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus 23:545\u2013553","journal-title":"Lupus"},{"key":"3140_CR7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.01.005","volume":"48\u201349","author":"X Xiao","year":"2014","unstructured":"Xiao X, Chang C (2014) Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 48\u201349:66\u201372","journal-title":"J Autoimmun"},{"key":"3140_CR8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203309106176","volume":"18","author":"AV Marzano","year":"2009","unstructured":"Marzano AV, Vezzoli P, Crosti C (2009) Drug-induced lupus: an update on its dermatologic aspects. Lupus 18:935\u2013940","journal-title":"Lupus"},{"key":"3140_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14740338.2015.995089","volume":"14","author":"RL Rubin","year":"2015","unstructured":"Rubin RL (2015) Drug-induced lupus. Expert Opin Drug Saf 14:361\u2013378","journal-title":"Expert Opin Drug Saf"},{"key":"3140_CR10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10067-009-1130-2","volume":"28","author":"AA Shabana","year":"2009","unstructured":"Shabana AA, El-Ghawet AE, Machaly SA, Hashim EMA, El-Kady BA, Shaat R (2009) Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus. Clin Rheumatol 28:673\u2013678","journal-title":"Clin Rheumatol"},{"key":"3140_CR11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/rheumatology\/kei227","volume":"45","author":"P Pallotta","year":"2006","unstructured":"Pallotta P, Cianchini G, Ruffelli M, Puddu P (2006) Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford) 45:116\u2013117","journal-title":"Rheumatology (Oxford)"},{"key":"3140_CR12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.1780371002","volume":"37","author":"JD Mountz","year":"1994","unstructured":"Mountz JD, Wu J, Cheng J, Zhou T (1994) Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 37:1415\u20131420","journal-title":"Arthritis Rheum"},{"key":"3140_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1169-8330(02)00311-3","volume":"69","author":"J Sibilia","year":"2002","unstructured":"Sibilia J (2002) Les Lupus induits par les medicaments. Rev Rheum 69:355\u2013369","journal-title":"Rev Rheum"},{"key":"3140_CR14","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/ar1440","volume":"6","author":"C Ferraro-Peyret","year":"2004","unstructured":"Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535\u2013R543","journal-title":"Arthritis Res Ther"},{"key":"3140_CR15","doi-asserted-by":"crossref","first-page":"R264","DOI":"10.1186\/ar1173","volume":"6","author":"F Bobbio-Palavicini","year":"2004","unstructured":"Bobbio-Palavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:R264\u2013R272","journal-title":"Arthritis Res Ther"},{"key":"3140_CR16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson C, Engstrand S, Sundqvist K-G, Rantap\u00e4\u00e4-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti- TNF\u03b1. Ann Rheum Dis 64:403\u2013407","journal-title":"Ann Rheum Dis"},{"key":"3140_CR17","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","volume":"52","author":"L Rycke De","year":"2005","unstructured":"De Rycke L, Baeten D, Kruithof E, van den Bosch F, Veys EM, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-double strand DNA autoantibodies as main antinuclear reactivity\u2014biological and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192\u20132201","journal-title":"Arthritis Rheum"},{"key":"3140_CR18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","volume":"11","author":"S Nancey","year":"2005","unstructured":"Nancey S, Blanvillain E, Parmentier B, Flouri\u00e9 B, Bayet C, Bienvenu J et al (2005) Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn\u2019s disease. Inflamm Bowel Dis 11:986\u2013991","journal-title":"Inflamm Bowel Dis"},{"key":"3140_CR19","first-page":"121","volume":"58","author":"A Hoxha","year":"2006","unstructured":"Hoxha A, Ruffatti A, Grypiotis P, Podswiadek M, Botsios C, Fiocco U et al (2006) Gli autoanticorpi antinucleo, anti-dsDNA, anti-ENA nei pazienti con artrite reumatoide o spondilite anchilosante in trattamento con infliximab. Reumatismo 58:121\u2013126","journal-title":"Reumatismo"},{"key":"3140_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1590\/S0482-50042010000300003","volume":"50","author":"VST Viana","year":"2010","unstructured":"Viana VST, Carvalho JF, Moraes JCB, Saad CG, Ribeiro AC, Gon\u00e7alves C et al (2010) Autoantibodies in patients with psoriatic arthritis on anti-TNF\u03b1 therapy. Rev Bras Reumatol 50:225\u2013234","journal-title":"Rev Bras Reumatol"},{"key":"3140_CR21","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2133.2011.10555.x","volume":"165","author":"JHO Hoffmann","year":"2011","unstructured":"Hoffmann JHO, Hartmann M, Enk AH, Hadaschik EN (2011) Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. BJD 165:1355\u20131358","journal-title":"BJD"},{"key":"3140_CR22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/S0482-50042013000400008","volume":"53","author":"JLP Vaz","year":"2013","unstructured":"Vaz JLP, Andrade CAF, Pereira AC, Martins MFM, Levy RA (2013) Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol 53:358\u2013364","journal-title":"Rev Bras Reumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-3140-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3140-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:59:28Z","timestamp":1559105968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-3140-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3140"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-3140-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,17]]}}}